Please try another search
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Toru Kawanishi | 55 | 2013 | Co-Founder & Executive Chairman |
Keita Mori | 55 | 2013 | Co-Founder, President, Executive Officer, CEO & Representative Director |
Yoichi Sato | 70 | 2019 | External Auditor |
Masaaki Tanahashi | 62 | 2018 | External Auditor |
Toshimichi Ueda | 57 | 2013 | External Auditor |
Noboru Kotani | 68 | 2013 | Independent External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review